Herein, in part of this work, we report that the engrafted protein drug PMIBcr/Abl‐R6 is able to achieve interaction between Bcr‐Abl and MDM2‐E3 ligase at the same time and act as a Bcr/Abl‐targeting PROTAC drug, inhibiting the growth of imatinib‐resistant Ph+ leukemia cells and patient‐derived cancer cells, including cells with the T315I mutation. This evidence concerns the gene BCR and cancer.